2-(5-methyl-2-phenyl-4-oxazolylmethoxy)pyridine-5-carbaldehyde | 157169-76-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(5-methyl-2-phenyl-4-oxazolylmethoxy)pyridine-5-carbaldehyde
• 英文别名: 5-formyl-2-(5-methyl-2-phenyl-4-oxazolylmethoxy)pyridine；6-(5-methyl-2-phenyl-4-oxazolylmethoxy)pyridine-3-carbaldehyde；6-(5-methyl-2-phenyl-4-oxazolylmethoxy)nicotinaldehyde；2-(5-methyl-2-phenyl-4-oxazolylmethoxy)-5-pyridinecarboxyaldehyde；6-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]pyridine-3-carbaldehyde
• CAS: 157169-76-1
• 化学式: C₁₇H₁₄N₂O₃
• 分子量: 294.31
• InChiKey: PSNMFPPNXZXVKI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  65.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(5-methyl-2-phenyl-4-oxazolylmethoxy)pyridine-5-carbaldehyde 在 sodium borohydrid 作用下， 以 tetrahydrofuran (150 ml)-methanol 、 水 为溶剂， 以95%的产率得到2-(5-methyl-2-phenyl-4-oxazolylmethoxy)pyridine-5-methanol
  参考文献：
  名称：

  EP1229026

  摘要：

  公开号：

文献信息

• Thiazolidinedione derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05489602A1

  公开（公告）日：1996-02-06

  The object of the present invention is to provide a new thiazolidinedione derivative exhibiting excellent hypoglycemic and hypolipidemic action. Thiazolidinedione derivative represented by the general formula: ##STR1## wherein n represents an integer from 1 to 3; A represents an aromatic 5-membered heterocyclic ring residue which has at least one nitrogen atom as a ring component atom, which is bound via a carbon atom adjacent to the nitrogen atom and which may be substituted; .cndot..cndot..cndot..cndot..cndot..cndot..cndot..cndot. is a single bond or a double bond, or pharmacologically acceptable salt thereof, is novel, and shows excellent hypoglycemic and hypolipidemic action.

  本发明的目的是提供一种展现出优异降糖和降脂作用的新噻唑烷二酮衍生物。通式表示的噻唑烷二酮衍生物如下：其中n代表1至3的整数；A代表至少有一个氮原子作为环组分原子的芳香5-成员杂环环残基，通过邻近氮原子的碳原子结合，且可能被取代；...是单键或双键，或其药理学可接受的盐，是新颖的，并展现出优异的降糖和降脂作用。
• Five-membered heterocyclic alkanoic acid derivative
  申请人：——

  公开号：US20040063775A1

  公开（公告）日：2004-04-01

  The present invention relates to a compound represented by the formula 1 wherein R 1 is an optionally substituted 5-membered heterocyclic group; X is a bond etc.; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; Y is a bond etc.; ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is —(CH 2 ) n —Z 1 — (n is an integer of 0 to 8 and Z 1 is a bond etc.) and the like; ring B is a 5-membered heterocycle optionally further having 1 to 3 substituents; W is a divalent saturated hydrocarbon group having 1 to 20 carbon atoms; R 2 is —OH etc., or a salt thereof. A pharmaceutical composition containing this compound is useful as a prophylactic or therapeutic agent of diseases such as diabetes mellitus and the like.

  本发明涉及一种由式1表示的化合物，其中R1是可选择取代的5元杂环基团; X是一个键等; Q是具有1到20个碳原子的双价碳氢基团; Y是一个键等; 环A是一个芳香环，可选择进一步具有1到3个取代基; Z是—(CH2)n—Z1—(n为0到8的整数，Z1是一个键等)等; 环B是一个可选择进一步具有1到3个取代基的5元杂环; W是具有1到20个碳原子的双价饱和碳氢基团; R2是—OH等，或其盐。包含该化合物的制药组合物可用作糖尿病等疾病的预防或治疗剂。
• Alkanoic acid derivatives process for their production and use thereof
  申请人：——

  公开号：US20040058965A1

  公开（公告）日：2004-03-25

  An alkanoic acid derivative useful as a prophylactic or therapeutic agent of diabetes mellitus, hyperlipidemia, impaired glucose tolerance and the like can be provided by a compound represented by the formula 1 wherein R 1 is an optionally substituted 5-membered aromatic heterocyclic group; X is a bond and the like; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; Y is a bond and the like, ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is —(CH 2 ) n —Z 1 — (n is an integer of 1 to 8 and Z 1 is an oxygen atom and the like) and the like; ring B is a pyridine ring optionally further having 1 to 3 substituents, and the like; U is a bond and the like; W is a divalent hydrocarbon group having 1 to 20 carbon atoms; and R 3 is —OH and the like, provided that, when ring B is a benzene ring optionally further having 1 to 3 substituents, U should be a bond, or a salt thereof.

  一种可以用作糖尿病、高脂血症、糖耐量受损等预防或治疗剂的脂肪酸衍生物可以由以下式1所表示的化合物提供，其中R1是可选取代的5-成员芳香杂环基；X是键等；Q是具有1到20个碳原子的二价碳氢基团；Y是键等；环A是一种芳香环，可选择进一步具有1到3个取代基；Z是—（CH2）n—Z1—（n是1到8的整数，Z1是氧原子等）等；环B是吡啶环，可选择进一步具有1到3个取代基等；U是键等；W是具有1到20个碳原子的二价碳氢基团；R3是—OH等；但是，当环B是苯环，可选择进一步具有1到3个取代基时，U应为键，或其盐。
• 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07179823B1

  公开（公告）日：2007-02-20

  A compound of formula (I) F wherein R1 represents a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; x represents a bond, an oxygen atom, a sulfur atom, or a group of the formula: —CO—, —CS—, —CR4(OR5)— or —NR6— wherein each of R4 and R6 represents a hydrogen atom or a hydrocarbon group which may be stubstituted, R5 represents a hydrogen atom or a protective group for a hydroxyl group; m represents an integer of 0 to 3; Y represents an oxygen atom, a sulfur atom, or a group of the formula: —SO—, —SO2—, —NR7—, —CONR7— or —NR7CO— wherein R7 represents a hydrogen atom or a hydrocarbon group which may be substituted; ring A represents an aromatic ring which may further have 1 to 3 substituents; n represents an integer of 1 to 8; ring B represents a nitrogen-containing 5-membered hetero ring which may further be substituted by an alkyl group.

  化合物的式子为（I）F，其中R1代表一个可以被取代的碳氢基团或杂环基团；x代表一个键、一个氧原子、一个硫原子或者一个式子为：—CO—、—CS—、—CR4(OR5)—或—NR6—的基团，其中R4和R6分别代表一个氢原子或者一个可以被取代的碳氢基团，R5代表一个氢原子或者一个羟基的保护基团；m代表一个0到3的整数；Y代表一个氧原子、一个硫原子或者一个式子为：—SO—、—SO2—、—NR7—、—CONR7—或—NR7CO—的基团，其中R7代表一个氢原子或者一个可以被取代的碳氢基团；环A代表一个芳香环，可以有1到3个取代基；n代表一个1到8的整数；环B代表一个含氮的5元杂环，可以有一个烷基的取代基。
• ALKOXYIMINOALKANOIC ACID DERIVATIVES
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1229026A1

  公开（公告）日：2002-08-07

  A compound represented by the formula    wherein R1is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; Xis a bond, an oxygen atom, a sulfur atom, or a group represented by -CO-, -CS-, -CR6(OR7)- or -NR8- (R6 and R8 are each a hydrogen atom or an optionally substituted hydrocarbon group, and R7 is a hydrogen atom or a hydroxy-protecting group); nis an integer of 0 to 3; Yis an oxygen atom, a sulfur atom, or a group represented by -SO-, -SO2-, -NR8-, -CONR8- or -NR8CO- (R8 is a hydrogen atom or an optionally substituted hydrocarbon group); ring Ais a heterocycle optionally having 1 to 3 additional substituents or a hydrocarbon ring optionally having 1 to 3 additional substituents; pis an integer of 1 to 8; R2is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; qis an integer of 0 to 6; mis 0 or 1; R3is a group represented by -OR9 (R9 is a hydrogen, atom or an optionally substituted hydrocarbon group) or -NR10R11 (R10 and R11 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, or an optionally substituted acyl group, and R10 and R11 may be taken together to form a ring); R4 and R5are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, and R4 and R2 may be taken together to form a ring, provided that, when ring A is an optionally substituted indole, Y is not an oxygen atom or a sulfur atom; when Y is an oxygen atom, a sulfur atom, -SO-, -SO2- or -NR8- (R8 is as defined above), ring A is not a benzene ring optionally having substituents; and when Y is an oxygen atom and ring A is an optionally substituted . 4-pyrone, an optionally substituted 4-pyridone or an optionally substituted pyridine-N-oxide, R2 is not a thiazole substituted by an optionally protected amino group or a thiadiazole substituted by an optionally protected amino group, and a salt thereof are useful as an agent for the prophylaxis or treatment of diabetes and the like.

  一种由式表示的化合物 式中 R1 是任选取代的烃基或任选取代的杂环基； X是键、氧原子、硫原子或由-CO-、-CS-、-CR6(OR7)-或-NR8-代表的基团（R6和R8各自是氢原子或任选取代的烃基，R7是氢原子或羟基保护基团）； n 是 0 至 3 的整数； Y是氧原子、硫原子或由-SO-、-SO2-、-NR8-、-CONR8-或-NR8CO-代表的基团（R8是氢原子或任选取代的烃基）； 环 A 是可选具有 1 至 3 个额外取代基的杂环或可选具有 1 至 3 个额外取代基的烃环； p 是 1 至 8 的整数； R2 是氢原子、任选取代的烃基或任选取代的杂环基； q 是 0 至 6 的整数； mis 0 或 1； R3是由-OR9（R9是氢原子或任选取代的烃基）或-NR10R11（R10和R11相同或不同，各自是氢原子、任选取代的烃基、任选取代的杂环基团或任选取代的酰基，R10和R11可结合在一起形成一个环）代表的基团； R4 和 R5 相同或不同，且各自为氢原子或任选取代的烃基，R4 和 R2 可结合在一起形成一个环，条件是当环 A 是任选取代的吲哚时，Y 不是氧原子或硫原子；当 Y 是氧原子、硫原子、-SO-、-SO2- 或 -NR8- （R8 如上定义）时，环 A 不是任选具有取代基的苯环；当 Y 是氧原子且环 A 是任选取代的.4-吡啶酮、任选取代的 4-吡啶酮或任选取代的吡啶-N-氧化物时，R2 不是被任选保护的氨基取代的噻唑或被任选保护的氨基取代的噻二唑、 及其盐可作为预防或治疗糖尿病等疾病的药物。